IPO Year: 2024
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/2/2024 | Buy | TD Cowen | |
| 7/2/2024 | $35.00 | Buy | Jefferies |
| 7/2/2024 | $35.00 | Buy | Stifel |
Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
TD Cowen initiated coverage of Rapport Therapeutics with a rating of Buy
Jefferies initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00
Stifel initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13D - Rapport Therapeutics, Inc. (0002012593) (Subject)
BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (NASDAQ:RAPP), please note the references to the AMPA-associated protein, TARP8 have been updated to the correct term, TARPγ8. The omission was due to a conversion issue when the release was formatted for distribution. The revised release follows: In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomical expression of TARPγ8 was confirmed In the MAD-2 trial, RAP-219 was observed to be generally well toler
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomical expression of TARP8 was confirmed In the MAD-2 trial, RAP-219 was observed to be generally well tolerated with faster titration and higher exposures than in the initial MAD trial Data underscore the potential broad therapeutic index of RAP-219 and dosing flexibility Ongoing Phase 2a trial of RAP-219 in focal epilepsy is on track and topline data is expected in mid-2025 BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage bio
A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies Change in long episode frequency is the primary endpoint for Rapport's ongoing Phase 2a proof-of-concept trial in focal epilepsy, with topline data expected in mid-2025 Data from additional studies, including preclinical seizure data and Phase 1 pharmacokinetic and safety trial results, support the potential of RAP-219 as a transformational treatment for patients with focal epilepsy BOSTON and LOS ANGELES, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-s
BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting, taking place December 6-10, 2024, in Los Angeles. Using analysis from an open-label, long-term treatment study of the RNS® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal electrographic activity) and clinically meaningful reduction ( 50
Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is
BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will participate in fireside chats at two upcoming investor conferences as follows: The Stifel Healthcare Conference in New York CityMonday, November 18, 2024, at 1:15pm ET The Jefferies London Healthcare ConferenceWednesday, November 20, 2024, at 4:00pm GMT/11am ET Interested parties may access the live and archived webcasts under the "Investors" section of the company's website
BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced presentations at two upcoming medical conferences: the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress (EEC) in Rome, Italy, September 7-11, 2024, and the 2024 Epilepsy Foundation Pipeline Conference in Atlanta, Ga., September 25-26, 2024. At EEC, Rapport will present on the novel design of a Phase 2a proof-of-concept trial for the company's lead product
BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences: The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Thursday, September 5, 2024, at 4:50 pm ET.TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Virtual) on Thursday, September 26, 2024, at 11:40 am ET. Interested parties may access a live and archived webcast of the Morgan Stanley
- Strengthened Board and management with appointments of experienced biotech leaders Troy Ignelzi, Sarah Boyce, John Healy and Kristina Haeckl - - Strong cash position of $219 million at the end of Q2 will support multiple clinical readouts - Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "Our tea
Completed initial public offering, raising $174.4 million in gross proceeds, including full exercise of the underwriters' option to purchase additional shares and a concurrent private placement, to fund clinical development of precision neuroscience pipelinePhase 2a trial of RAP-219 in focal epilepsy initiation on track, with topline data expected in mid-2025 On track to begin two additional proof of concept clinical trials of RAP-219 in patients with peripheral neuropathic pain in 2H 2024, and patients with bipolar disorder in 2025Terry-Ann Burrell, who was recently appointed as vice chairman of investment banking at JPMorgan, will transition off the Board of Directors of Rapport following
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
3 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
3 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
3 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
3 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)
8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)
8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)